LONDON--(BUSINESS WIRE)--Technavio’s latest market research report on the global primary biliary cholangitis therapeutics market predicts the market to witness a CAGR of close to 10% during the forecast period. This research report segments the market by product (OCALIVA, ursodiol, and others) and geography (North America, Europe, Asia, and ROW).
Advent of regenerative therapy
The recurring nature of primary biliary cholangitis is one of the major challenges faced in the global market. As currently there is no cure for the indication except for liver transplantation, the market witnesses a need for curative therapy. As a result, various researchers are conducting studies on developing regenerative therapies that could ensure the complete remission of the indication to overcome this challenge and capture the huge unmet need. Although the research on the use of stem cell transplantation is still in the nascent stages, and the mechanism of the therapy is still not known to the researchers, advances stem cell transplantation are expected to add significant value to the global primary biliary cholangitis market growth during the forecast period.
OCALIVA product segment will garner the highest share
OCALIVA was the largest segment of the global primary biliary cholangitis therapeutics market in 2018 and is expected to grow faster than the overall market during the forecast period. OCALIVA was developed for the treatment of various liver-related indications, with primary biliary cholangitis being the main indication. It is currently the most preferred drug for the treatment of the indication due to its strong efficacy to target the T-cells that are known to cause primary biliary cholangitis. As a result, the adoption of OCALIVA is expected to increase significantly during the next five years.
“The treatment using OCALIVA has provided positive results. Moreover, the side effects associated with the use of OCALIVA are milder than other drugs such as URSO 250 and URSO Forte. The risk of possible side effects of OCALIVA can also be decreased by changing the dosage or the duration of the drug, which will further contribute to the growing demand for this drug globally,” says a senior research analyst at Technavio
Looking for more information on this market? Request a free sample report
Primary biliary cholangitis therapeutics to witness fastest adoption in Europe.
Europe is expected to emerge as the fastest growing region of the global primary biliary cholangitis therapeutics market during the forecast period owing to the increasing prevalence and the incidence of the indication in most developed countries in this region. The advanced healthcare infrastructure in the region is also helping in overcome the challenges associated with the diagnosis and the treatment of the indication. Furthermore, growing awareness about the disease due to initiatives taken by various vendors and other organizations are expected to drive the growth of the primary biliary cholangitis therapeutics market in the region.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the global primary biliary cholangitis therapeutics market analysis include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio is a leading global technology research and advisory company. It provides detailed market research reports that provide clients with actionable insights to help them identify market opportunities and design effective strategies to optimize their market position.
With over 500 specialized analysts, Technavio boasts of an extensive report library comprising of over 10,000 reports, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than a hundred Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets. Technavio helps companies to assess their competitive position within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
